The Graves’ Ophthalmopathy drugs in development market research report provides comprehensive information on the therapeutics under development for Graves’ Ophthalmopathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Graves’ Ophthalmopathy. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Graves’ Ophthalmopathy and features dormant and discontinued products.

GlobalData tracks 26 drugs in development for Graves’ Ophthalmopathy by 26 companies/universities/institutes. The top development phase for Graves’ Ophthalmopathy is phase ii with nine drugs in that stage. The Graves’ Ophthalmopathy pipeline has 25 drugs in development by companies and one by universities/ institutes. Some of the companies in the Graves’ Ophthalmopathy pipeline products market are: Viridian Therapeutics, Zenas BioPharma (USA) and Suzhou Pro-Heal Pharmaceutical Technology.

The key targets in the Graves’ Ophthalmopathy pipeline products market include Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1), IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN), and Thyrotropin Receptor (Thyroid Stimulating Hormone Receptor or TSHR).

The key mechanisms of action in the Graves’ Ophthalmopathy pipeline product include Insulin Like Growth Factor 1 Receptor (CD221 or IGF1R or EC 2.7.10.1) Antagonist with seven drugs in Phase III. The Graves’ Ophthalmopathy pipeline products include eight routes of administration with the top ROA being Subcutaneous and six key molecule types in the Graves’ Ophthalmopathy pipeline products market including Monoclonal Antibody, and Small Molecule.

Graves’ Ophthalmopathy overview

Graves’ ophthalmopathy is an autoimmune condition where the thyroid gland mistakenly senses harmful cells and releases antibodies to combat them. Since there are no harmful cells, the released antibodies end up fusing with muscles in the eyes, causing the onset of Graves’ ophthalmopathy. Symptoms include eye redness, eye inflammation, eyelid retraction, and eye weakness. Treatment includes radioiodine therapy, anti-thyroid medications, and thyroid surgery.

For a complete picture of Graves’ Ophthalmopathy’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.